公司資料
Angion Biomedica 股價、新聞與催化劑
- 股票代碼:
- ANGN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for ANGN.
公司概覽
業務概覽
Angion Biomedica was a development-stage biotech focused on kidney disease, inflammation, and organ-protection biology. Its story was built around a narrow set of programs trying to create value in hard-to-treat indications.
所在地與產業分類
Angion was headquartered in the United States and listed on NASDAQ. It sat in small-cap biotechnology with a translational medicine profile.
商業模式特徵
The company depended on clinical progress, target validation, and capital management to keep programs moving. Investors typically focused on early readouts, pipeline prioritization, and whether the biology could support a durable asset.
生技產業定位
Angion occupied a classic small-cap biotech niche where a limited pipeline and limited runway made the stock highly sensitive to data and financing.
未來催化劑
- Angion Biomedica is a legacy / closeout story, with catalysts limited to any residual asset or corporate update. There is no active standalone pipeline driving the name.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。